AMS Nabs Option to License Sinclair IS Pharma's Antibiofilm for Woundcare ...

Advanced Medical Solutions (AMS) negotiated a six-month option to exclusively license Sinclair IS Pharma’s Delmopinol antibiofilm technology for the development of foam-based woundcare dressings. Working with University collaborators AMS has already evaluated the efficacy of Delmpinol in a range of in vitro models to assess its potential in combination with its own anti-microbial woundcare dressing.

The firm will now carry out further R&D and feasibility testing for up to six months before deciding on whether to license the technology for the designated indication. “Our R&D program has been looking into ways to control biofilms within chronic wounds in order to further improve the efficacy of our dressings,” notes Chris Meredith, AMS CEO.